359 related articles for article (PubMed ID: 30391138)
1. Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.
Saad AM; Gad MM; Al-Husseini MJ; Ruhban IA; Sonbol MB; Ho TH
Clin Genitourin Cancer; 2019 Feb; 17(1):46-57.e5. PubMed ID: 30391138
[TBL] [Abstract][Full Text] [Related]
2. Has Stage Migration in Renal Cancer Run Its Course? A SEER Database Analysis.
Haifler M; Neheman A; Zisman A
Clin Genitourin Cancer; 2020 Aug; 18(4):e368-e373. PubMed ID: 32089472
[TBL] [Abstract][Full Text] [Related]
3. Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data.
Smaldone MC; Egleston B; Hollingsworth JM; Hollenbeck BK; Miller DC; Morgan TM; Kim SP; Malhotra A; Handorf E; Wong YN; Uzzo RG; Kutikov A
Med Care; 2017 Apr; 55(4):398-404. PubMed ID: 27820596
[TBL] [Abstract][Full Text] [Related]
4. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract][Full Text] [Related]
5. Rising incidence of small renal masses: a need to reassess treatment effect.
Hollingsworth JM; Miller DC; Daignault S; Hollenbeck BK
J Natl Cancer Inst; 2006 Sep; 98(18):1331-4. PubMed ID: 16985252
[TBL] [Abstract][Full Text] [Related]
6. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010.
King SC; Pollack LA; Li J; King JB; Master VA
J Urol; 2014 Jun; 191(6):1665-70. PubMed ID: 24423441
[TBL] [Abstract][Full Text] [Related]
7. Trends in cause of death among patients with renal cell carcinoma in the United States: a SEER-based study.
Zhan X; Chen T; Liu Y; Wan H; Liu X; Deng X; Fu B; Xiong J
BMC Public Health; 2023 Apr; 23(1):770. PubMed ID: 37101189
[TBL] [Abstract][Full Text] [Related]
8. International variations and trends in renal cell carcinoma incidence and mortality.
Znaor A; Lortet-Tieulent J; Laversanne M; Jemal A; Bray F
Eur Urol; 2015 Mar; 67(3):519-30. PubMed ID: 25449206
[TBL] [Abstract][Full Text] [Related]
9. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of laterality in renal cell carcinoma: A population-based study from the surveillance, epidemiology, and end results (SEER) database.
Guo S; Yao K; He X; Wu S; Ye Y; Chen J; Wu CL
Cancer Med; 2019 Sep; 8(12):5629-5637. PubMed ID: 31407495
[TBL] [Abstract][Full Text] [Related]
11. Rising incidence of renal cell cancer in the United States.
Chow WH; Devesa SS; Warren JL; Fraumeni JF
JAMA; 1999 May; 281(17):1628-31. PubMed ID: 10235157
[TBL] [Abstract][Full Text] [Related]
12. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis.
Sun M; Thuret R; Abdollah F; Lughezzani G; Schmitges J; Tian Z; Shariat SF; Montorsi F; Patard JJ; Perrotte P; Karakiewicz PI
Eur Urol; 2011 Jan; 59(1):135-41. PubMed ID: 21035250
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of patients diagnosed with both melanoma and renal cell cancer.
Abern MR; Tsivian M; Coogan CL; Kaufman HL; Polascik TJ
Cancer Causes Control; 2013 Nov; 24(11):1925-33. PubMed ID: 23897487
[TBL] [Abstract][Full Text] [Related]
14. Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program.
Shuch B; Hofmann JN; Merino MJ; Nix JW; Vourganti S; Linehan WM; Schwartz K; Ruterbusch JJ; Colt JS; Purdue MP; Chow WH
Urol Oncol; 2014 Jan; 32(1):23.e9-13. PubMed ID: 23453468
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for metachronous bilateral renal cell carcinoma: A surveillance, epidemiology, and end results analysis.
Syed JS; Nguyen KA; Holford TR; Hofmann JN; Shuch B
Cancer; 2019 Jan; 125(2):232-238. PubMed ID: 30561791
[TBL] [Abstract][Full Text] [Related]
16. Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors.
Rabbani F; Herr HW; Almahmeed T; Russo P
J Clin Oncol; 2002 May; 20(9):2370-5. PubMed ID: 11981010
[TBL] [Abstract][Full Text] [Related]
17. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
[TBL] [Abstract][Full Text] [Related]
18. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
[TBL] [Abstract][Full Text] [Related]
19. Tumor laterality in renal cancer as a predictor of survival in large patient cohorts: A STROBE compliant study.
Strauss A; Uhlig J; Lotz J; Trojan L; Uhlig A
Medicine (Baltimore); 2019 Apr; 98(17):e15346. PubMed ID: 31027111
[TBL] [Abstract][Full Text] [Related]
20. Impact of gender in renal cell carcinoma: an analysis of the SEER database.
Aron M; Nguyen MM; Stein RJ; Gill IS
Eur Urol; 2008 Jul; 54(1):133-40. PubMed ID: 18160207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
